| Expression pattern: |
DN |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Serves as a clinically accessible liquid biopsy biomarker for HCC screening; its expression is lower in HCC tissues and blood from HCC patients than in adjacent noncancerous liver tissues or normal people. |
| Molecular mechanism: |
Not specified as a disease mechanism; the study focuses on nanobiosensor-based recognition of the cSMARCA5 back-splice junction through CHA cascade amplification and magnetic control depuration for quantitative detection. |
| Biological pathway or process: |
not specified |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation |
| Clinical significance: |
Downregulated cSMARCA5 can be used as a biomarker to screen and differentiate HCC patients from normal people in liver tissue and whole blood samples. |
| Description: |
This study developed and clinically validated a CHA cascade amplification and magnetic control depuration nanobiosensor to quantify cSMARCA5 in liver tissue and whole blood. cSMARCA5 was significantly downregulated in HCC tissues and peripheral venous blood from HCC patients, and its measurement could differentiate HCC patients from normal people, supporting its use as a liquid biopsy biomarker for HCC screening. |
| Confidence score: |
0.2995 |